Jessica Legrange
Psychiatric/Mental Health · Oklahoma City, OKNPI 1801466644
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 255 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,184 and has fallen 90.4% since, to $210 in 2025.
Across 255 payments — averaging $20.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$852
- Johnson & Johnson$631
- AbbVie$599
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$521
- Lundbeck LLC$448
- Teva Pharmaceuticals USA, Inc.$431
- plus $2K from 13 others
What the payments were for
- Food & beverage$5,03499%
- Education$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 31 | $852 |
| Johnson & Johnson | 41 | $631 |
| AbbVie | 31 | $599 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 22 | $521 |
| Lundbeck LLC | 24 | $448 |
| Teva Pharmaceuticals USA, Inc. | 23 | $431 |
| Otsuka America Pharmaceutical, Inc. | 24 | $375 |
| Vanda Pharmaceuticals Inc. | 13 | $257 |
| Sunovion Pharmaceuticals Inc. | 11 | $223 |
| Neurocrine Biosciences, Inc. | 8 | $155 |
| E.r. Squibb & Sons, L.L.C. | 4 | $147 |
| Indivior Inc. | 8 | $141 |
| Corium, LLC | 4 | $88 |
| Ironshore Pharmaceuticals Inc. | 4 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $55 |
| Supernus Pharmaceuticals, Inc. | 1 | $30 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Noven Therapeutics, LLC | 2 | $27 |
| Tris Pharma Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$469
- LYBALVI$467
- VRAYLAR$228
- INVEGA SUSTENNA$123
- AUSTEDO$117
- ARISTADA INITIO$117
- COBENFY$116
- CAPLYTA$113
How this compares
$5,109 in reported general payments places this provider in the 85th percentile of 231 psychiatric/mental health providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 65 | $206,056 |
| Abilify MaintenaAripiprazole | 20 | $57,425 |
| VraylarCariprazine Hcl | 12 | $20,498 |
| Hydroxyzine Hcl | 67 | $2,086 |
| Aripiprazole | 78 | $1,979 |
| Lurasidone Hcl | 31 | $1,800 |
| Duloxetine Hcl | 65 | $1,649 |
| Quetiapine Fumarate | 67 | $1,554 |
| Buspirone Hcl | 75 | $1,552 |
| Ziprasidone Hcl | 21 | $1,416 |
| Doxepin Hcl | 30 | $1,326 |
| Hydroxyzine Pamoate | 26 | $1,221 |
| Bupropion XlBupropion Hcl | 47 | $1,175 |
| Oxcarbazepine | 20 | $1,169 |
| Trazodone Hcl | 98 | $930 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $631 | $206,05665 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $375 | $57,42520 claims |
| AbbVieVraylar | $599 | $20,49812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 231 psychiatric/mental health providers in Oklahoma.
Other psychiatric/mental health in Oklahoma City
- Sylvie MawohOklahoma City$14K
- Imelda GarnerOklahoma City$9K
- Kathryn SheltonOklahoma City$8K
- Nicole BrownOklahoma City$8K
- Ragina HolimanOklahoma City$7K
- Tierra PageOklahoma City$7K
- Kelsey WilsonOklahoma City$6K
- Jamie HolzOklahoma City$6K
- Robin Potter-KimballOklahoma City$6K
- Sue RollinsOklahoma City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.